Geron Corp (Nasdaq: GERN) announced the publication of preclinical data demonstrating activity of the company's telomerase inhibitor drug, imetelstat, on ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE